Drug intelligence / Profile preview

Pnemotex

Development stage: Unknown
Lead developer: Nanolek
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**Pnemotex** is a Russian-approved, adsorbed 13-valent pneumococcal polysaccharide conjugate vaccine developed and manufactured by Nanolek for prevention of pneumococcal infection in individuals from 2 months of age through adulthood. It contains capsular polysaccharides from *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F conjugated to the CRM197 carrier protein and adsorbed to aluminum phosphate. Vaccination elicits serotype-specific antibodies against pneumococcal capsular polysaccharides, supporting protection against disease caused by the included serotypes. ([nanolek.ru](https://nanolek.ru/en/portfolio/pnemotex/))

Brand names: PnemotexПнемотекс

Targets

SpCPS1 (Streptococcus pneumoniae capsular polysaccharide serotype 1)CPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)19A CPS (Streptococcus pneumoniae serotype 19A capsular polysaccharide)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)PPS3 (Streptococcus pneumoniae serotype 3 capsular polysaccharide)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)PPS5 (Streptococcus pneumoniae capsular polysaccharide serotype 5)6A CPS (Streptococcus pneumoniae serotype 6A capsular polysaccharide)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)

Beyond the preview

Go deeper on Pnemotex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pnemotex.